Header Ads Widget



Oxford Drug Design raises £2.2M to...

Roundup: Oxford Drug Design raises £2.2M to develop AI program, RuneLabs launches Portuguese subsidiary to improve diabetes care, more briefs

Oxford Drug Design raises £2.2M to develop AI-based drug discovery program

Biotechnology firm Oxford Drug Design Ltd (ODD) has raised £2.2M in funding from existing investors ACF Investors, o2h Ventures, Meltwind Advisory, several returning angels and new investors, and US-based R42 Group.

An Oxford University spinout has created an artificial intelligence (AI) AI proprietary platform for drug discovery, focused on therapeutic needs in oncology.

ODD CEO Alan de Roth said: “This latest funding will enable us to build on and accelerate our successful computational design-based discovery focus. We are a key driver in the innovation of oncological treatments that deliver improved outcomes for cancer patients around the world. Excited to play the role.”

Rune Labs launches Portuguese subsidiary to improve diabetes care

Precision Neurology Software and Data Platform Company rune labs A team of leading designers based in Lisbon, Portugal has announced the creation.

The new team will focus on expanding the facilities and workflow for Rune Labs’ DrivePD ecosystem for Parkinson’s care. Subsidiary Rune will also have its first permanent presence in Europe.

Will Newby, VP of Product, Rune Labs, said: “Rune Labs is focused on enabling human-centered care for people living with Parkinson’s, and the Portugal team of product designers will ensure that patients, clinicians and researchers Be our voice. Product.”

Babylon GP at Hand opens two new clinics in London

Babylon GP at Hand has opened two new clinics in London that will provide patients with their digital-first integrated care as well as face-to-face appointments.

The first clinic in Victoria’s Dean Farrar Street opened last week and will be followed by a clinic in Euston’s Drummond Street next month.

Dr Matthew Noble, UK Medical Director, Babylon, said: “Highly accessible digital appointments as well as personalized care are very important and we are really excited to launch these two new clinics for our Babylon GP in hand patients in London Excited.”

CDP Venture Capital launches Digital Health Startup Accelerator

CDP Venture Capital Sgr has announced the launch of an accelerator for digital health startups with a focus on innovative solutions for respiratory diseases, ophthalmology, women’s health, rare diseases and chronic pain management.

The VITA program has been set up in association with Healthware Group and Danish accelerator Acceleres, with total assets under management of 6.35 million.

Roberto Accione, CEO and Founder of Healthware Group, said: “The Vita Accelerator is a testament to Healthware’s commitment to contributing to the digital health transformation, supporting the growth and development of the most promising startups.”

applications are open For Italian startups and international startups intending to set up registered offices in Italy by 12 June.

Clinical trial shows blood test can identify 79% of early-stage bowel cancers

A primary care clinical trial in West Wales found that a blood test was able to detect 79% of early-stage bowel cancer and 100% of advanced bowel cancer.

Raman spectrometry (RS) blood test was developed by a Swansea University spin-out cansenseWith funding from Cancer Research Wales and Health and Care Research Wales.

Can sense has also received £1.2 million from the National Institute for Health and Care Research (NIHR) to further develop the blood test for use in clinical practice in Wales.

Dr. Cerise Jenkins, Co-Founder and Director of CanSense, said: “Having this test available in the triage phase will save time, money, but most importantly, save patients' anxiety and unnecessary clinical trials. Will go.”

AI Cancer Diagnostics Company wins Life Science Innovation Award

British AI startup Behold.AI has won Best UK Digital Health Solution at the Prix Galleon Awards.

The firm was awarded for its Red Dot® clinical analysis software for X-ray detection of lung cancer, which is in use at several NHS hospital sites as part of an independent validation on patient data.

Simon Raslingam, CEO and chairman of Behold.AI, said: “The peer-reviews we’ve done show that if we roll out this technology nationally we can add the equivalent of 233 NHS consultant radiologists, who That equates to 255,000 hours of consultant time per year.”

Post a Comment